Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
COGT Stock Chart & Stats
$38.36
-$0.07(-0.91%)
At close: 4:00 PM EST
$38.36
-$0.07(-0.91%)
Day’s Range― - ―
52-Week Range$3.72 - $43.73
Previous CloseN/A
Volume181.15K
Average Volume (3M)2.28M
Market Cap
$5.83B
Enterprise Value$5.66B
Total Cash (Recent Filing)$390.89M
Total Debt (Recent Filing)$60.56M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Mar 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding152,053,960
10 Day Avg. Volume2,542,149
30 Day Avg. Volume2,276,195
Financial Highlights & Ratios
PEG Ratio-1.92
Price to Book (P/B)3.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.89
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.89K
Enterprise Value/Ebitda-19.02
Forecast
1Y Price Target
$50.33Price Target Upside31.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In Second-line GISTCombination data showing substantially longer progression-free survival and higher response rates versus sunitinib alone supports potential adoption of the regimen as a new standard of care in second-line gastrointestinal stromal tumors.
Pipeline Diversification And Commercial UpsidePlanned development of pan-KRAS and selective JAK2 programs plus anticipated approvals in mastocytosis and GIST expand the addressable market and create upside beyond current revenue models.
Regulatory ProgressBreakthrough Therapy designation for the combination therapy and multiple planned NDA submissions across mastocytosis and gastrointestinal stromal tumor indications may speed regulatory reviews and create several approval pathways.
Bears Say
Comparative Clinical CompetitivenessA lower overall response rate versus a leading competitor and continued tolerability concerns may hinder the drug's ability to fully displace established therapies in key indications.
Emerging Late-stage CompetitionInvestor concern about a rival program entering late-stage development for second-line GIST raises the risk of future competition that could pressure pricing, market share, and commercial forecasts.
Safety Profile And MonitoringTransient but serious liver enzyme elevations and a higher rate of adverse events relative to some comparators increase the likelihood of post-approval safety monitoring, dose modifications, or label restrictions that could limit uptake.
Cogent Biosciences News
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $3.72 and its highest was $43.73 in the past 12 months.
What is Cogent Biosciences’s market cap?
Cogent Biosciences’s market cap is $5.83B.
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is Mar 17, 2026 which is in 46 days.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on Nov 03, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.516 by $0.016.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -0.51.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 152,053,960 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.516. Following the earnings report the stock price went down -4.908%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Currently, no hedge funds are holding shares in COGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogent Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.33 (31.20% Upside)
$50.33 (31.20% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 9.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $139.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
329.56%
12-Months-Change
Fundamentals
Return on Equity
-95.40%
Trailing 12-Months
Asset Growth
10.92%
Trailing 12-Months
Company Description
Cogent Biosciences
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
COGT Stock 12 Month Forecast
Average Price Target
$50.33
▲(31.20% Upside)
Technical Analysis
IDEAYA Biosciences
―
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
Currently, No data available
---